Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[68Ga]Ga-NOTA-HL
- Development stage
- Unknown
- Lead developer
- National Atomic Research Institute
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
\[68Ga\]Ga-NOTA-HL (also known as Ga-68 Dolacga) is a gallium-68 labeled radiopharmaceutical developed by the National Atomic Research Institute (NARI, formerly the Institute of Nuclear Energy Research) in Taiwan. It is a PET imaging tracer designed to target the asialoglycoprotein receptor (ASGPR) on hepatocytes. ASGPR is a transmembrane protein highly expressed on the sinusoidal and basolateral surfaces of functional hepatocytes, making it a valuable biomarker for assessing functional liver reserve. The tracer consists of a hexavalent lactoside (HL) ligand conjugated to a 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) chelator, which is radiolabeled with gallium-68. It is formulated as a lyophilized kit (Dolacga) for rapid, one-step preparation. It is being evaluated in clinical trials for preoperative liver function assessment in patients with liver cancer (such as hepatocellular carcinoma) and for monitoring liver function changes before and after treatments like proton therapy or radiofrequency ablation.
- Brand names
- Dolacga
- Other names
- 68Ga-NOTA-HL68Ga-NOTA-hexavalent lactosideGa-68 DolacgaGa68 DolacgaGa 68 DolacgaGa-68 NOTA-HLGa68 NOTA-HLGa 68 NOTA-HLGa68-DolacgaGa-68-DolacgaGa 68-DolacgaGa68-INER038Ga-68-INER038Ga 68-INER038gallium Ga-68 NOTA-HLgallium Ga-68 NOTA-hexavalent lactoside
02
Targets
ASGPR (Asialoglycoprotein Receptor 1)
Beyond the preview
Go deeper on [68Ga]Ga-NOTA-HL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [68Ga]Ga-NOTA-HL.